Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. The company's commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. The company's products include: EYLEA (aflibercept) injectio, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.
  • TickerREGN
  • ISINUS75886F1075
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for REGN

ValuEngine Rating and Forecast Report for REGN

Regeneron Pharmaceuticals Inc: 3 directors sold after exercising options/sold

Three Directors at Regeneron Pharmaceuticals Inc sold after exercising options/sold 10,633 shares at between 488.413USD and 494.278USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where t...

Dominic Rose ...
  • Naresh Chouhan

Intron Health - COVID-19 - $10bn Sales Opportunity for New Drugs

As the situation continues to deteriorate in the West and evidence grows of a second wave in some East Asian countries, the need for a therapeutic solution that could help to stem the tide is now crucial. With a COVID-19 vaccine unlikely until mid-2021 and given early signs of mutations which may temper vaccine efficacy, drugs could help to ease the burden on hospitals. We show there is a potential $10bn windfall to be shared between 4 BioPharma companies. We conclude that Roche is best placed in EU Pharma due to an Actemra boost, CV-19 testing windfall & defensive portfolio. For access to th...

ValuEngine Rating and Forecast Report for REGN

ValuEngine Rating and Forecast Report for REGN

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold and...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold and...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of names in the Communications Sector are showing signs of leadership. (ex. GLUU, and CNSL) • Consumer Discretionary continues to have a number of attractive names technically. (ex. TXRH, BLMN, WEN, CBRL, SCI, LL, and STMP) • Healthcare has a number of attractive names technically. (ex. SEM, CYH, THC, PRSC, TRHC, HQY, GILD, EBS, REGN, and ABBV) • REIT's remain a leadership Sector (ex. STAR, HR, SAFE, DLR, SBAC, and EQIX)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weighte...

Regeneron Pharmaceuticals Inc: 3 directors sold after exercising options/sold

Three Directors at Regeneron Pharmaceuticals Inc sold after exercising options/sold 10,633 shares at between 488.413USD and 494.278USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where t...

Valens Research

Valens Equity Insights and Inflections - 2020 01 28

HGV currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 16.6x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to decline from 16% in 2018 to 8% in 2023, accompanied by 8% Uniform Asset growth. Meanwhile, analysts have similar expectations, projecting Uniform ROA to fade to 12% by 2020, accompanied by immaterial Uniform Asset shrinkage. Meanwhile, management generated an excitement marker when talking about their data systems, and they are confident about their interest rates and contract sales. Current valuations appe...

Valens Research

REGN - Embedded Expectations Analysis - 2020 01 22

 Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost management  Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack confi...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior